TLR4 agonists as vaccine adjuvants: a&#160;chemist's perspective (Q43603547)

25 November 2017

0 references

TLR4 agonists as vaccine adjuvants: a chemist's perspective (English)

1 reference

25 November 2017

0 references

David A Johnson

1

1 reference

25 November 2017

1 July 2013

1 reference

Expert Review of Vaccines

25 November 2017

3

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 November 2017

12

1 reference

25 November 2017

7

1 reference

25 November 2017

711-713

1 reference

How do adjuvants work? Important considerations for new generation adjuvants

25 November 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

The safety evaluation of adjuvants during vaccine development: the AS04 experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Synthesis and immunomodulatory activities of Helicobacter pylori lipophilic terminus of lipopolysaccharide including lipid A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Mechanisms of alcohol liver damage: aldehydes, scavenger receptors, and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

Increased immunogenicity to P815 cells modified with malondialdehyde and acetaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811189

10.1586/14760584.2013.811189

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

23885814